Hawaii currently does not license nonresident pharmaceutical facilities other than pharmacies. A draft rule now in front of the Hawaii Board of Pharmacy would change that.

What Hawaii's Proposed Rule Would Require

At its July 23, 2026 meeting, the Hawaii Board of Pharmacy reviewed a full draft amendment to Hawaii Administrative Rules Chapter 95, the rule governing pharmacists and pharmacies in the state. That draft includes a change to Section 16-95-31, the rule governing Hawaii's Miscellaneous Permit.

The document's own color coding marks the entire list of business types eligible for a Miscellaneous Permit as new proposed text, not existing rule language. That list includes two categories that were not there before: an outsourcing facility registered under Section 503B of the Federal Food, Drug, and Cosmetic Act, and a wholesale prescription drug distributor.

In plain terms: Hawaii is proposing to require nonresident wholesale distributors and 503B outsourcing facilities to hold a Hawaii Miscellaneous Permit before they can legally do business in the state.

Why This Matters

If you operate as a nonresident wholesale distributor or outsourcing facility doing business in Hawaii today without holding a Hawaii permit, you are not violating any current rule. Hawaii officials confirmed that the state does not currently license nonresident facilities other than pharmacies. 

The proposed Miscellaneous Permit application would also require:

• Verification of a valid, unexpired license or registration in good standing from the applicant's home state
• The two most recent certifications and documentation required by whichever agency governs the applicant's business type, including the FDA or a state board of pharmacy
• The name and license status of the Pharmacist-in-Charge and any other employed pharmacists
• Disclosure of the applicant's principal corporate officers
• An attestation that the applicant has no history of state or federal drug law violations

This is not a lighter-touch registration as it requires the same amount of information Hawaii already requires from wholesale distributors licensed within the state.

The Groundwork Is Already Visible

At the same meeting, the Board reviewed a Final Report from a Permitted Interaction Group (PIG) assigned to evaluate the Miscellaneous Permit application process. The PIG recommended revising the application to clearly define an applicant's scope of business and require supporting documents, such as recent facility inspection reports, so the Board receives complete information upfront instead of sending repeated follow-up requests.

That recommendation lines up with a board preparing to process an entirely new population of applicants, not adjusting a permit it already processes at high volume. Bringing wholesale distributors and outsourcing facilities into this permit category for the first time is exactly the kind of change that would prompt a board to tighten its intake process beforehand.

The same draft also revises Section 16-95-30, the wholesale prescription drug distributor license requirements, in the same amendment package. Revising both sections together shows the Board is building a coordinated licensing path for nonresident entities, not making an isolated edit to a single rule.

One of the Last States with Minimal Nonresident Requirements

If adopted, the rule would take Hawaii off the short list of states with limited licensing requirements for nonresident facilities.

Per Pennsylvania Department of Health guidance, nonresident facilities must register only if they have sales representatives physically working in the state or if they distribute or manufacture finished List I products, such as pseudoephedrine tablets, into the state.

Massachusetts licenses nonresident pharmacies and nonresident 503B outsourcing facilities, but the Board has said it has no plans to license nonresident wholesalers, distributors, 3PLs, or manufacturers.

If Hawaii's proposed rule is adopted, it would join the majority of states that require nonresident licensure, leaving Pennsylvania and Massachusetts as the remaining outliers for most facility types.

Next Steps

The Hawaii Board of Pharmacy held a review meeting on September 24, 2026. LighthouseAI will watch for the meeting minutes when they are published, and they will provide the clearest indication of where this proposed permit requirement is headed and what timeline affected companies should plan around.

Stay Ahead of Regulatory Change With LighthouseAI

Hawaii's proposed permit requirement is one of hundreds of regulatory changes that affect pharmaceutical supply chain licensing every year. When these changes take effect, companies that are not prepared face immediate compliance exposure.

LighthouseAI's Selective Notifications deliver automated regulatory monitoring alerts tailored to your license portfolio, so your team is always informed of new and changing requirements across all 56 US jurisdictions before they affect your operations.

Never miss a new or changing state licensing requirement. Request a Demo‍